NDA 215833 · Novartis
Pluvicto
Lutetium Lu-177 Vipivotide Tetraxetan · Intravenous · Radioligand Therapeutic Agent
NovelBreakthrough therapyPriority reviewCDER novel approval, Mar 23, 2022: To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Mar 23, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
36
4 Phase 3, 19 recruiting
FAERS reports
13,841
3,364 serious, 1,680 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 12, 2026.
PLUVICTO is a radioligand therapeutic agent indicated: Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. ( 1.1 ) Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy. ( 1.2 ) 1.1 Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. 1.2 Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy.
Mechanism: Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177 which is linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. Upon binding of lutetium Lu 177 vipivotide tetraxetan to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to PSMA-expressing cells, as well as to surrounding cells, and induces DNA damage which can lead to cell death.
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 2026 Supplement 37 · Efficacy LetterLabel
- Mar 28, 2025 Supplement 21 · Efficacy LabelLetter
- Mar 23, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- PLUVICTO · LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27mCi/ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lutetium Lu-177 Vipivotide Tetraxetan" as an intervention, any sponsor and status, largest first.
- A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06320067 · 3,360 participants (planned) · Start Jun 11, 2024 · Primary completion Apr 2031
Drug: Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI) and 1 more · For: Prostate Cancer Metastatic
Sites: Barnsley, United Kingdom; Cambridge, United Kingdom; Exeter, United Kingdom · 18 sites in all
- Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07200830 · 1,524 participants (planned) · Start Mar 31, 2026 · Primary completion Sep 9, 2034
Drug: Lutetium Lu 177 Vipivotide Tetraxetan · For: Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Anchorage, Alaska; Bakersfield, California; Irvine, California · 142 sites in all
- Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05803941 · 700 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 20, 2033
Drug: AAA617 · For: Prostate Cancer
Sites: Scottsdale, Arizona; Orange, California; Santa Monica, California · 54 sites in all
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06632977 · 474 participants (planned) · Start Feb 6, 2025 · Primary completion Apr 11, 2030
Drug: Valemetostat Tosylate; Carboplatin and 4 more · For: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Birmingham, Alabama; Tucson, Arizona; Chico, California · 108 sites in all
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05939414 · 450 participants (planned) · Start Mar 12, 2024 · Primary completion Apr 25, 2028
Drug: AAA617; piflufolastat (18F) and 1 more · For: Oligometastatic Prostate Cancer (OMPC)
Sites: Fayetteville, Arkansas; Los Angeles, California; Palo Alto, California · 144 sites in all
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerPivotal-lookingNot yet recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT07852195 · 432 participants (planned) · Start Jan 6, 2027 · Primary completion Mar 31, 2029
Drug: Abiraterone Acetate; Cabazitaxel and 8 more · For: Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095089 · 355 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 21, 2027
Drug: JNJ-78278343; JNJ-87189401 and 3 more · For: Prostatic Neoplasms
Sites: Aurora, Colorado; Atlanta, Georgia; Minneapolis, Minnesota · 22 sites in all
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05818683 · 300 participants (planned) · Start Apr 26, 2023 · Primary completion Aug 31, 2027
Drug: Pasritamig; Cetrelimab and 8 more · For: Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer
Sites: Sarasota, Florida; Grand Rapids, Michigan; Brooklyn, Mississippi · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- general physical health deterioration6,684
- ill-defined disorder3,641
- death1,321
- disease progression360
- malignant neoplasm progression343
- prostatic specific antigen increased287
- laboratory test abnormal266
- fatigue238
- anaemia204
- platelet count decreased168
- hormone-refractory prostate cancer167
- illness165
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2022 | 622 |
| 2023 | 3,535 |
| 2024 | 3,984 |
| 2025 | 3,457 |
| 2026 | 2,242 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, et al. · Clin Cancer Res 2023 · Randomized Controlled Trial, Multicenter Study
- Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.
Patell K, Kurian M, Garcia JA, et al. · Expert Rev Anticancer Ther 2023 · Systematic Review
- Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
Soon YY, Marschner IC, Schou M, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.